Nov 2026· Frontiers in Immunology· Vol 17· 0 citations· 78 references
TL;DR
It is argued that clinically useful eosinophil biomarkers will require integration of abundance with phenotype, spatial localization, tissue compartment, and treatment context, and that most reported associations remain prognostic rather than demonstrated predictors of treatment benefit.
Abstract
Eosinophils, traditionally associated with type 2 immunity, are increasingly recognized as context-dependent regulators of cancer immunity. Their effects are not intrinsically anti-tumorigenic or pro-tumorigenic but are shaped by five partially distinct dimensions of context: tumor type and stage, anatomical compartment and microlocalization, cytokine milieu and activation state, the circulating-versus-tissue compartment, and treatment exposure. This Review critically synthesizes mechanistic and clinical evidence defining this functional plasticity, with explicit separation of murine and human evidence throughout. Eosinophils can directly kill tumor cells through granule proteins and reactive oxygen species, recruit and activate cytotoxic lymphocytes, promote vascular normalization, and participate in interleukin-33-dependent anti-tumor circuits. In other settings, they can facilitate metastatic dissemination, angiogenesis, tissue remodeling, and immune suppression. These opposing functions help explain the heterogeneous clinical associations reported across malignancies. Tissue eosinophils at the invasive tumor front are associated with longer time to recurrence in colorectal cancer, whereas peripheral eosinophil dynamics have emerged as candidate biomarkers during immune checkpoint inhibitor therapy in non-small cell lung cancer; eosinophilic malignant pleural effusion may also define a distinct prognostic subgroup. We critically distinguish prognostic, predictive, and pharmacodynamic biomarker claims, and emphasize that most reported associations remain prognostic rather than demonstrated predictors of treatment benefit. We further discuss therapeutic opportunities involving the interleukin-5/interleukin-33/eotaxin axis, induced eosinophils, and eosinophil-assisted cellular therapy, graded by their level of clinical maturity and weighed against the risks of systemic eosinophil activation. We argue that clinically useful eosinophil biomarkers will require integration of abundance with phenotype, spatial localization, tissue compartment, and treatment context. This framework clarifies when eosinophils are protective, harmful, or therapeutically exploitable and highlights priorities for prospective human studies in cancer immunology and precision immunotherapy.
Despite the traditional view of neutrophils as primarily antibacterial cells, emerging evidence has highlighted their significant involvement in cancer progression and the modulation of the tumor microenvironment (TME). Tumor-associated neutrophils (TANs) have been recognized as key players in various malignancies, exe...
K. Saleh, Moamin Mohammad Khdir, S. Jyothi et al.· Immunotherapy· 0 citations
BACKGROUND
Prostate cancer (PCa), the most frequently diagnosed malignancy in men, shows only limited responses to conventional immunotherapeutic strategies, largely attributed to its immunologically "cold" tumor microenvironment (TME), which is characterized by myeloid cell populations and comparatively sparse infiltr...
F. Melchior, S. Salcher, A. Pircher et al.· Translational Oncology· 0 citations
The immune microenvironment of colorectal cancer (CRC) is characterized by pronounced cellular-state and spatial heterogeneity. B cells and macrophages bridge adaptive and innate immunity, respectively, and engage in bidirectional regulation through antibodies and immune complexes, BAFF/APRIL signaling, cytokines, chem...
Zhang Zhang, Ying-Chao Zhang, Jing Lin et al.· Frontiers in Immunology· 0 citations
It is proposed that B cells support anti-tumor immunity when integrated into organized lymphoid niches and engaged in productive T cell-B cell cooperation, whereas they promote immune escape when redirected toward regulatory programs or suppressive myeloid interactions.
Yi-Nuo Wang, Xuan Che, Xiao-Qian Hu et al.· Critical reviews in oncology...· 0 citations
Immune‐cell dynamics within the tumor microenvironment (TME) determine whether immune cells can reach, recognize, and sustain antitumor function against malignant cells under suppressive pressure. These dynamics are shaped by hypoxia, nutrient stress, cytokine and chemokine signaling, stromal architecture, vascular acc...
Pin Guo, Yi-Zhao Xie, R. Song et al.· MedComm· 0 citations
Neutrophils, once viewed as short-lived and functionally uniform antimicrobial cells, are now recognized as highly plastic immune regulators with context-dependent roles in cancer. Among circulating neutrophil subsets, low-density neutrophils (LDNs) have emerged as a clinically relevant population in oncology due to th...
T. Martins, R. Salvador, B. Correia et al.· Journal of Leukocyte Biology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.